5岁以上骨硬化症患者的干细胞移植
本文报告7例5至30岁(平均15岁,中位12岁)中间型骨硬化症患者接受造血干细胞移植,病因为TCIRG1、CLCN7、RANK、SNX10及CA2突变,供者包括匹配同胞或家属、匹配无关及单倍体相合家属,预处理以氟达拉滨和白消安为基础。6例匹配供者移植患者均存活,随访1至8年(中位4年),症状及生活质量显著改善。作者认为中间型骨硬化症患者应考虑造血干细胞移植。
要点
- 7例5至30岁中间型骨硬化症患者接受HSCT,6例匹配供者移植者均存活。
- 随访1至8年(中位4年),存活者症状及生活质量显著改善。
- 作者认为中间型骨硬化症患者应考虑HSCT。
核心结论
- 作者认为中间型骨硬化症患者应考虑造血干细胞移植。
研究设计与样本
- 本文报告7例由TCIRG1(n=2)、CLCN7(n=2)、RANK(n=1)、SNX10(n=1)和CA2(n=1)突变所致中间型骨硬化症患者,移植时年龄5至30岁(平均15岁,中位12岁)。
- 供者为匹配同胞或家属(n=4)、匹配无关供者(n=2)或HLA单倍体相合家属供者(n=1),预处理以氟达拉滨和白消安为基础。
主要发现
- 6例匹配供者移植患者目前均存活,发表时随访1至8年(中位4年),症状及生活质量显著改善。
临床怎么用
- 作者认为中间型骨硬化症患者应考虑造血干细胞移植。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Osteopetrosis (OP) is a rare disease caused by defective osteoclast differentiation or function. Hematopoietic stem cell transplantation (HSCT) is the only curative treatment available in the infantile "malignant" form of OP. Improved clinical and genetic diagnosis of OP has seen the emergence of a cohort of patients with less severe and heterogeneous clinical presentations. This intermediate form of OP does not call for urgent intervention, but patients accumulate debilitating skeletal complications over years and decades, which are severe enough to require curative treatment and may also require intermittent transfusion of blood products. Here we present data from 7 patients with intermediate OP caused by mutations in TCIRG1 (n = 2), CLCN7 (n = 2), RANK (n = 1), SNX10 (n = 1), and CA2 (n = 1), who were transplanted between the ages of 5 to 30 years (mean, 15; median, 12). Donors were matched siblings or family (n = 4), matched unrelated (n = 2), or HLA haploidentical family donors (n = 1). Conditioning was fludarabine and treosulfan based. All 6 patients transplanted from matched donors are currently alive with a follow-up period between 1 and 8 years at time of publication (median, 4 years) and have demonstrated a significant improvement in symptoms and quality of life. Patients with intermediate OP should be considered for HSCT.
引用
- Stepensky P, Grisariu S, Avni B, et al. Stem cell transplantation for osteopetrosis in patients beyond the age of 5 years. Blood Adv. 2019. PMID: 30885997. doi:10.1182/bloodadvances.2018025890
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。